• 855-853-4760
  • customerservice@arevapharma.com

Media Center

Areva Pharmaceuticals is excited to announce three new products to our ever-expanding portfolio:

Areva Pharmaceuticals would like to announce the addition of Irinotecan HCL Injection 300mg/15ml to our existing Irinotecan family that includes 40mg/2ml and 100mg/5ml. Irinotecan is used alone or in a combination with other medications to treat colon or rectal cancer (cancer that begins in the large intestine.) Irinotecan is in a class of antineoplastic medications called topoisomerase I inhibitors which works by stopping the growth of cancer cells. This product is in a liquid form and is given intravenously over a 90-minute time period. Irinotecan is sometimes used with other medications to treat small cell lung cancer.